Re: Bill 33, Safeguarding our Communities Act (Fentanyl Patch for Patch Return Policy), 2015
|
|
- Beatrice Melton
- 5 years ago
- Views:
Transcription
1 November 30, 2015 Mr. Peter Tabuns Chair, Standing Committee on Social Policy 99 Wellesley Street West, Room 1405 Whitney Block Queen's Park Toronto, ON M7A 1A2 Dear Mr. Tabuns: Re: Bill 33, Safeguarding our Communities Act (Fentanyl Patch for Patch Return Policy), 2015 The Ontario Pharmacists Association (the Association, OPA ) appreciates the opportunity to present commentary on behalf of the profession of pharmacy to the Standing Committee on Social Policy on Bill 33, Safeguarding our Communities Act (Fentanyl Patch for Patch Return Policy), OPA advocates for the profession of pharmacy in Ontario, where more than 20,000 pharmacists, pharmacists-in-training and pharmacy technicians who actively practice in community pharmacies, family health teams, long term care facilities, and hospital clinical settings, as well as for those in industry, private businesses, insurance, and government. Consistent with the core objectives of inspiring excellence in the profession and its practices, advocating for the wellness of the patients we serve, and the daily experiences of more than 9,500 members practicing in close to 4,000 clinical settings, we are pleased to provide the following comments for your consideration of the proposed bill. The scourge of drug abuse, including drug diversion, continues to threaten safety and security in every Ontario community, and indeed the country, and the Ontario Pharmacists Association acknowledges the many efforts made at the local, municipal, provincial and federal levels to curb such activities for the protection of Ontarians and indeed all Canadians. Most notable at the front lines in this war on drug abuse, misuse and diversion are Ontario s community pharmacists and pharmacy technicians who, as vigilant gatekeepers of our drug supply, protect our communities as they ensure that narcotic, controlled and targeted substances are provided to the right patient, at the right dose, at the right time and for the right purpose and in accordance with rigid protocols and standards of practice. They are perhaps the most at risk of all healthcare providers in this war as they alone physically stand between the substances of choice and the users, many of whom have and will continue to resort to threats and violence when their drugseeking strategies are thwarted. On November 1, 2011, the Narcotics Safety and Awareness Act, 2010 ( NSAA ) came into effect with the aim to improve the health and safety of Ontarians by promoting appropriate prescribing 1
2 and dispensing practices for narcotics and other controlled substances, identifying and reducing the abuse, misuse and diversion of these drugs and reducing the risk of addiction and death from the abuse or misuse of these drugs. Among the first strategies to be put in place with the Act was the implementation of a narcotic monitoring system ( NMS ) that was intended to track the dispensing of prescription narcotic, controlled and targeted substances while collecting information to better support appropriate prescribing and dispensing behaviours. OPA is on record with its support of the NSAA, but recognized that the NMS while being a good first step in the fight against abuse, misuse and diversion was an information tracking system at best. To be truly effective, OPA s position was that information needs to be evaluated, shared and corresponding best practices developed in order to drive appropriate prescribing and dispensing. Such information sharing with pharmacy and medical practitioners has yet to occur since the electronic NMS became fully functional in April Nonetheless, with the NMS tracking in place, a strong message was sent to drug users and diverters that they were under scrutiny and it would become more and more difficult to obtain prescriptions for narcotic, controlled or targeted substances. With the discontinuation of OxyContin (oxycodone) in early 2012 and its replacement with tamper-resistant OxyNEO, an even stronger message was sent, and while tamper-resistance did not imply tamper-proof, the switch in formulation triggered a shift to an alternative substance of choice of users; aside from the escalation in heroin use, fentanyl patches became the new OxyContin. For an overview of fentanyl and its formulation, please refer to Appendix A. The Association commends the Member from Nipissing, Mr. Victor Fedeli, for acknowledging through Bill 33 the severity of fentanyl abuse and its devastating impact on Ontario communities and taking a step to mitigate diversion of new and used patches. As with all government or regulatory initiatives that potentially impact the profession of pharmacy, OPA carefully examined Bill 33 for both its intended and potential unintended consequences. On first glance, the concept of introducing greater controls on the dispensing through a mandated patch-for-patch ( P4P ) program seemed plausible, but on further analysis, the Association identified some challenges and concerns that need to be raised with both the Standing Committee on Social Policy and the Ministry of Health and Long-Term Care. The challenges and concerns with a mandated P4P program as expressed in Bill 33 touch on matters related to provider health and safety, societal influences, legislative process, professional judgment and professional misconduct, and operational impact. Health and Safety Concerns: In the matter of dispensing narcotic, controlled and targeted substances, OPA is particularly concerned with the inherent risks for pharmacists and pharmacy technicians. Integral to the P4P programs in place voluntarily across the province comes the risk of fentanyl toxicity and potential contamination associated with the physical inspection of returned used patches. In many cases, patches are returned in ways that do not permit close or even accurate visual inspection. They may be placed back loosely within the pouch from the manufacturer, stuck or stapled to a piece 2
3 of paper, wrapped in plastic wrap, or encased in clear tape or foil. Through Bill 33, clause 3(1)(4) requires the dispenser to inspect every used fentanyl patch collected from the patient or his or her authorized representative. Users and diverters have become quite adept at rendering the used patches more difficult to scrutinize, thereby leaving the pharmacist to question the authenticity of the returned product. In addition to the serious health and safety risks of toxicity and contamination comes the risks associated with finding a counterfeit product within the return or where a patch has been lost, tampered with or destroyed beyond recognition and is incapable of being authenticated. Clause 3(1)(5) indicates that the dispenser is only permitted to dispense patches in accordance with the contingency plan established under the regulations. Irrespective of any regulatory contingency plan that results in the dispensing of fewer patches than the patient/agent anticipates, it is not unreasonable for said patient/agent to become hostile and possibly violent. Personal safety and security for pharmacists and technicians is of paramount importance to OPA, and mandating pharmacy team members to act as police, judge and jury with respect to patch validation will undoubtedly place them at increased risk of harm, and is not consistent with their training as health care providers. Linked to risks associated with challenging a patient or agent on patch authenticity is the very real potential for P4P programs to shift users/diverters to more crude and extreme behaviours of pharmacy break-ins and armed robberies. Both are happening with increased frequency, and it is speculated that this may be due in part to the introduction of barriers such as narcotic monitoring systems and P4P programs, which make access to and diversion of targeted substances through the traditional prescription pathway more difficult. Societal Influence: The Association is very concerned with the unintended consequence of a mandated P4P program that is very product specific. As explained earlier in the document, this serious fentanyl problem was largely influenced by strong scrutiny on oxycodone prescribing and dispensing and the shift toward tamper-resistant formulations. It is therefore very reasonable to assume that stringent oversights on the prescribing and dispensing of fentanyl will surely shift behaviours toward yet another targeted substance without the same levels of scrutiny. This is not to suggest that nothing be done. Rather, it is the Association s recommendation that each initiative under consideration should be extremely well thought-out with input from all stakeholders and significant efforts undertaken to predict what the next new substance of choice will be. From the patient perspective, OPA has heard from our members that some patients are refusing to participate in regional P4P programs due to the social stigma associated with them. Should this program be mandated, many of those patients who truly need to be using fentanyl, will certainly be asking their prescriber to switch them to another medication so that they would not feel stigmatized by that process, which is concerning to OPA as this would prevent those legitimate patients from achieving their desired health outcomes. 3
4 Legislative Process: While the Association acknowledges the need for legislative intervention to address the serious concern of drug diversion and abuse, we are concerned that Bill 33 would be setting a precedent for drug-specific legislations, which will only have a short-term effect simply lasting until another drug becomes the new abused drug of choice. We suggest that a more effective approach would be to focus on tackling the issue of drug abuse and diversion in general, rather than focusing on one drug/medication at a time. This proposed approach would require ongoing, transparent and structured collaboration between prescribers, dispensers and law enforcement. OPA therefore suggests forming a task force which involves representatives from each of those sectors with the goal to explore and implement long-term sustainable solutions. Professional Judgment and Professional Misconduct: With the evolving needs of our patients, along with the expanding scope of practice, as pharmacy professionals, we continuously exercise professional judgment based on assessing each patient s unique needs and each situation s own facts and circumstances. Exercising professional judgment means that one pharmacist s assessment and decision may differ, not only from another colleague s, but also from one patient to another. In doing so, pharmacists ensure that their actions and decisions are always in the patient s best interest. This is an integral element of our everyday practice. OPA is therefore concerned that the proposed Bill could hinder a pharmacist s ability to exercise their professional judgment. Since neither legislations nor regulations could ever cover each possible exception that a pharmacist may encounter, OPA therefore questions how the regulatory College would view cases where pharmacy professionals might decide to exercise their judgement to contravene some aspects of the Patch for Patch program, when that decision is made solely in the best interest of the patient. Operational Impact: Pharmacy professionals strive to provide excellence in practice and care to their patients on a daily basis. While doing so, they constantly exercise zero tolerance for drug diversion and abuse. OPA supports community pharmacies that voluntarily choose to participate in the P4P program in their municipality. However, OPA is concerned that mandating such a program would put added strains on those pharmacies that do not have the capacity and/or resources to manage the additional administrative workload and logistics necessary to comply with the program s policies, such as drafting and maintaining individual patients contracts, inspecting used patches, ensuring required documentation is completed, denaturing and discarding of returned patches, etc. The Association therefore suggests that should a Bill like this one be enacted, adequate remuneration should be in place to support pharmacies in delivering on those administrative 4
5 requirements. OPA would welcome the opportunity to provide further breakdown of the anticipated costs and the suggested corresponding remuneration value. The Ontario Pharmacists Association appreciates the opportunity to present commentary on Bill 33, Safeguarding our Communities Act (Fentanyl Patch for Patch Return Policy), While we do applaud the initiative, we question whether there is any data collated or studies conducted that prove the efficacy of diversion programs. OPA believes that a broader strategy for tackling drug abuse, overdose and diversion is more warranted than the narrow-focused approach in the proposed Bill, and we therefore welcome the opportunity to be involved, and spearhead, such initiatives with the Ministry of Health and Long-Term Care, other health care providers, and law enforcement. The Association also strongly recommends that the Ontario government invests in technology, including the implementation of a comprehensive electronic prescribing system and a more robust and functional narcotic monitoring system. Yours truly, Dennis A. Darby, P.Eng., ICD.D Chief Executive Officer 5
6 Appendix A FENTANYL Overview Fentanyl is a powerful synthetic opiate analgesic similar to but more potent than morphine. It has typically been used to treat patients with severe pain, or to manage pain after surgery. It is also sometimes used to treat people with chronic pain who are physically tolerant to opiates. In its most commonly available format, fentanyl is delivered through a transdermal patch system and is intended to be used only on skin that is not irritated or injured. Each patch comes in an individually sealed pouch; once opened, care must be exercised so as not to touch the adhesive surface since it contains some of the active ingredient. Fentanyl is rapidly absorbed into the body via the skin of the hand. If accidental contact requires immediate rinsing of the area with plenty of clear water. Patches are never intended to be placed in the mouth, chewed, or swallowed. Each patch is a controlled delivery system designed to release a steady amount of medication over a 72-hour time period; damage to a patch may cause fentanyl to pass into the skin too quickly, leading to overdose. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, fentanyl patches should only be used in patients for whom alternative treatment options are ineffective or not tolerated (e.g., non-opioid analgesics), or would be otherwise inadequate to provide sufficient management of pain (e.g., immediaterelease opioids). Fentanyl patches pose risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Each patient s risk should be assessed prior to prescribing, and all patients should be monitored regularly for the development of these behaviours or conditions. All patients should be instructed to store their patches securely to avoid theft or misuse. 6
RE: PROPOSED AMENDMENTS TO REGULATIONS TO THE CONTROLLED DRUGS AND SUBSTANCES ACT
November 8, 2017 Ms. Michelle Boudreau Director General Controlled Substances Directorate Office of Legislative and Regulatory Affairs Health Canada 150 Tunney s Pasture Driveway, Main Stats Building Address
More informationReview of Controlled Drugs and Substances Act
Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A
More informationAppearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse
Opening Statement Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse Dr. Chris Simpson, President-elect
More informationOntario s Narcotics Strategy
Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action
More informationTable of Contents Interim Report of the OxyContin Task Force, Newfoundland & Labrador, January 30, 2004
OXYCONTIN TASK FORCE INTERIM REPORT January 30, 2004 Submitted to Hon. Elizabeth Marshall, Minister of Health & Community Services, Government of Newfoundland and Labrador Table of Contents INTRODUCTION
More informationRE: Proposed Amendments to the Pharmacy Act Regulations, O. Reg.202/94 General
May 27, 2016 Ontario College of Pharmacists Re: Open Consultation Feedback 483 Huron Street Toronto ON M5R 2R4 Dear Mr. Moleschi: RE: Proposed Amendments to the Pharmacy Act Regulations, O. Reg.202/94
More informationImplementation: Public Hearing: Request for Comments (FDA-2017-N-6502)
March 16, 2018 via online submission: www.regulations.gov The Honorable Scott Gottlieb Commissioner Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Opioid Policy Steering
More informationINTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D
INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D SIXTY-THIRD REGULAR SESSION April 25-27, 2018 México D.F., México OEA/Ser.L/XIV.2.63 CICAD/doc.2385/18 25 April 2018 Original: English THE OPIOID
More informationRe: Non-prescription availability of low-dose codeine products
2017 November 7 Michelle Boudreau Director General Legislative and Regulatory Affairs Controlled Substances Directorate Healthy Environments and Consumer Safety Branch Health Canada Address Locator: 0302A
More informationMinistry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference
Ministry of Health and Long-Term Care Presentation to the CPSO Methadone Prescribers Conference November 9, 2012 Overview Minister s Expert Working Group on Narcotic Addiction OxyNEO and OxyContin: Changes
More informationStrategies for Federal Agencies
Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid
More informationGOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE
POSITION PAPER GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE Governments across Canada are concerned about the abuse of prescription drugs, with recent policy discussions focused on mitigating
More informationSeptember 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201
September 1, 2017 The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Dear Secretary Price: The National Association of County
More informationA LOOK AT ABUSE-DETERRENT OPIOIDS
JULY 2017 Drugs Under Review ICER s report reviewed evidence on ten abuse-deterrent formulations (ADF) of opioids. Nine of the drugs were extended release (ER) opioids, and one was immediate release (IR).
More informationCardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention
Cardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention The people of Cardinal Health care deeply about the devastation opioid abuse has caused American families and communities
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationNotice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch
Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch Frequently Asked Questions 1. What is the new Health Network System feature
More informationRE: CONSULTATION ON DRAFT - DRUG AND NATURAL HEALTH PRODUCTS RECALL GUIDE
January 14, 2019 Health Products Compliance and Enforcement Unit Regulatory Operations and Regions Branch Health Canada By email to: hc.hpce-cpsal.sc@canada.ca RE: CONSULTATION ON DRAFT - DRUG AND NATURAL
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationJuly 6, Scott Gottlieb, MD Commissioner U.S. Food and Drug Administration New Hampshire Avenue Silver Spring, MD 20993
Scott Gottlieb, MD Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Draft Revisions to the Food and Drug Administration Blueprint for Prescriber Education
More informationOntario s Narcotics Strategy
Ontario Public Drug Programs Division Ontario s Narcotics Strategy Frequently Asked Questions This fact sheet provides basic information only. It must not take the place of medical advice, diagnosis or
More informationCMA Response: Health Canada s Medical Marihuana Regulatory Proposal. Submitted to the Office of Controlled Substances Health Canada.
CMA Response: Health Canada s Medical Marihuana Regulatory Proposal Submitted to the Office of Controlled Substances Health Canada February 28, 2013 A healthy population and a vibrant medical profession
More informationJanuary 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9
January 19, 2018 Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9 By email: cannabis@canada.ca RE: Proposed Approach to the Regulation of Cannabis
More informationThe Home Office Proposals to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001 January 2018
The Home Office Proposals to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001 January 2018 Prepared by: Adam Osprey Policy & Development Pharmacist adam.osprey@cps.scot Who
More informationNarcotics Monitoring System (NMS) Update
Narcotics Monitoring System (NMS) Update DISCLOSURE OF COMMERCIAL SUPPORT This program has received no financial or in-kind support. Potential for conflict(s) of interest: None Faculty/Presenter Disclosure
More informationCANNABIS IN ONTARIO S COMMUNITIES
CANNABIS IN ONTARIO S COMMUNITIES That municipal governments support their local Public Health Unit and encourage Develop a funded public health approach to cannabis legalization, regulation, restriction
More informationSafe Prescribing of Drugs with Potential for Misuse/Diversion
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
More informationFentanyl and Synthetic Opioids- Awareness and the Enforcement Pillar. July-16-18
Fentanyl and Synthetic Opioids- Awareness and the Enforcement Pillar Opioid Situation-How we got here 2012 Oxycontin moves to the tamper proof version OxyNeo (Purdue Pharma) 2012/2013 Patch diversion and
More informationMinister s Opioid Emergency Response Commission Recommendations to the Minister Updated July 5, 2018
The Minister s Opioid Emergency Response Commission was established May 31, 2017 to support the Government of Alberta s urgent response to the opioid crisis. As part of its mandate, the Commission is responsible
More informationThe Challenge of Treating Pain
FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and
More informationAmerican Academy of Pain Medicine American Pain Society American Society of Anesthesiologists
PAIN CARE COALITION A National Coalition for Responsible Pain Care American Academy of Pain Medicine American Pain Society American Society of Anesthesiologists August 29, 2017 The Honorable Chris Christie,
More informationNALOXONE RISK ASSESSMENT
NALOXONE RISK ASSESSMENT Intended audience: Non-public sector organizations. Introduction: BC is currently experiencing a public health emergency related to the unprecedented increase in opioid overdoses
More informationIncrease in Opioid Related Deaths What the Data Can Tell us. Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes
Increase in Opioid Related Deaths What the Data Can Tell us Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes Objectives Prescription Opioid Misuse and Abuse: How did we get here? Opioid
More informationSTATEMENT. of the. American Medical Association. for the Record. House Committee on Energy and Commerce
STATEMENT of the American Medical Association for the Record House Committee on Energy and Commerce RE: Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives October
More informationCOMMITMENT TO A TOBACCO ENDGAME IN ONTARIO
COMMITMENT TO A TOBACCO ENDGAME IN ONTARIO Our Ask That the Ontario government: Renew their commitment to achieving the lowest smoking rate in Canada Align the Smoke Free Ontario Strategy with the proposed
More informationStatement Of. The National Association of Chain Drug Stores. For. United States Senate Caucus on International Narcotics Control.
Statement Of The National Association of Chain Drug Stores For United States Senate Caucus on International Narcotics Control Hearing on: Improving Management 10:00 a.m. 226 Dirksen Senate Office Building
More informationRecommendations for Components of Emergency Department Discharge Protocols
Recommendations for Components of Emergency Department Discharge Protocols Background Maryland, like many other states, is in the midst of an opioid crisis. In 2016, 89 percent of all intoxication deaths
More informationIntroduction. Ron Taverner Superintendent, Toronto Police Service Chair, Substance Abuse Committee Ontario Association of Chiefs of Police
Ontario Association of Chiefs of Police Substance Abuse Committee 2014 Introduction This document is intended to provide a background and understanding of a Fentanyl Patch 4 Patch Initiative to law enforcement,
More informationChairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and
United States House of Representatives Committee on Energy and Commerce Subcommittee on Commerce, Manufacturing and Trade Hearing on Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield
More informationStandard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)
Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care) Preamble This Standard establishes the standards of practice and ethical requirements of all physicians
More informationStrategic Plan
2017-18 Strategic Plan 1 Strategic Planning Process The Summit County Opiate Task Force has made great strides in addressing the opiate crisis in the last few years. More than 100 Summit County citizens
More informationOntario s Narcotics Strategy
Ontario Public Drug Program Division Ontario s Narcotics Strategy Frequently Asked Questions This fact sheet provides basic information only. It must not take the place of medical advice, diagnosis or
More informationTitle of Session: Restricting the Marketing and Advertising of Opioids in Canada Date of Session: September 5, 2018
Title of Session: Restricting the Marketing and Advertising of Opioids in Canada Date of Session: September 5, 2018 Purpose To update stakeholders on Health Canada s actions to date, and to consult on
More informationRe: Draft Guideline for the Use of Opioids for Chronic Pain (Docket No. CDC )
January 13, 2016 Veronica Kennedy Acting Executive Secretary, Centers for Disease Control and Prevention National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770
More informationENABLING RECOVERY FROM COMMON TRAFFIC INJURIES: A FOCUS ON THE INJURED PERSON Response of the Ontario Physiotherapy Association
ENABLING RECOVERY FROM COMMON TRAFFIC INJURIES: A FOCUS ON THE INJURED PERSON Response of the Ontario Physiotherapy Association INTRODUCTION The Ontario Physiotherapy Association (OPA), a branch of the
More informationNeedle and Syringe Programs - 17 October 2013
Needle and Syringe Programs - 17 October 2013 ANCD Position Paper: Needle and Syringe Programs MEDIA RELEASE 17 October 2013 The Australian National Council on Drugs (ANCD) has today released a position
More informationNYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference. Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement.
NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement May 2, 2018 1 May 2, 2018 2 Bureau Overview May 2, 2018 3 HISTORY 1850--Bureau
More informationFentanyl, Opioid Overdose and Naloxone
Fentanyl, Opioid Overdose and Naloxone Opioid Agonist Therapy Conference Saskatoon, SK April, 2016 Declaration No conflict of interest. Consultant in Addiction Medicine, SHR. Chair, College of Physicians
More informationMark W. Caverly, Chief Liaison and Policy Section
DEA Issues: An Update Harold Rogers National Prescription Drug Monitoring Meeting Meeting September 24 25, 2009 Mark W. Caverly, Chief Liaison and Policy Section Prescription Drug Abuse Prescription Drug
More informationCare not Corrections SUMMARY REPORT APRIL Relieving the Opioid Crisis in Canada CANADIAN MENTAL HEALTH ASSOCIATION
Care not Corrections Relieving the Opioid Crisis in Canada CANADIAN MENTAL HEALTH ASSOCIATION SUMMARY REPORT APRIL 2018 SUMMARY REPORT Canada is confronting an unprecedented public health crisis. In 2016-2017,
More informationPennsylvania Prescription Drug Monitoring Program Trends,
DEA Intelligence Report Brief DEA-PHL-DIR-006-17 Pennsylvania Prescription Drug Monitoring Program Trends, 2014-2015 December 2016 1 Executive Summary The abuse and diversion of pharmaceutical drugs, particularly
More informationCONFRONTING THE OPIOID EPIDEMIC. e-book: Introducing OptumRx Opioid Risk Management
CONFRONTING THE OPIOID EPIDEMIC 2 0 1 8 OPIOID ABUSE IS A CRISIS IN THE U.S. OptumRx Opioid Risk Management attacks this complex, deeply embedded problem with a comprehensive approach featuring five interrelated
More informationCLEVELAND COUNTY MAY 8, 2018 PAGE 1
MAY 8, 2018 PAGE 1 The Cleveland County Board of Health met on Tuesday, May 8, 2018 at 6:00 p.m., at the Cleveland County Public Health Center. Board members present: Katie Borders, Street Hamrick, Randy
More informationOctober 15, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket No. FDA-2012-N-0548 To Whom It May Concern: The American Dental Association
More informationCannabis Legalization Proposed Bylaws
2018 April 03 Page 1 of 7 EXECUTIVE SUMMARY On 2017 April 13, the Government of Canada introduced Bill C-45, An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal
More informationCannabis Legalization August 22, Ministry of Attorney General Ministry of Finance
Cannabis Legalization August 22, 2018 Ministry of Attorney General Ministry of Finance Federal Cannabis Legalization and Regulation The federal Cannabis Act received Royal Assent on June 21, 2018 and will
More informationCSS Perspective - Opioid Risk Management
Tufts Health Care Institute Program on Opioid Risk Management Risk Evaluation and Mitigation Strategy for Prescription Opioids: An In-Depth Review of Fundamental Issues CSS Perspective - Opioid Risk Management
More informationUnderstanding the Opiate Epidemic
Understanding the Opiate Epidemic An opiate is a narcotic analgesic that depresses the central nervous system. Natural opiates are derived from the poppy plant. Synthetic opiates are manufactured drugs
More informationAddressing the Harms of Prescription Drugs in Canada
www.ccsa.ca www.cclt.ca Addressing the Harms of Prescription Drugs in Canada Innovations & Policy Solutions for Addressing Prescription Drug Abuse April 30, 2014 Rita Notarandrea, Canadian Centre on Substance
More informationSUBJECT: Cannabis legislation and implications for the City of Burlington
Page 1 of Report CM-11-17 SUBJECT: Cannabis legislation and implications for the City of Burlington TO: FROM: Committee of the Whole City Manager's Office Report Number: CM-11-17 Wards Affected: All File
More informationHouse Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515
February 28, 2018 The Honorable Michael Burgess, M.D. The Honorable Gene Green Chairman Ranking Member Subcommittee on Health Subcommittee on Health House Committee on Energy and Commerce House Committee
More informationJuly 6, Dear Governor Christie:
July 6, 2017 The Honorable Chris Christie Chair President s Commission on Combating Drug Addiction and the Opioid Crisis White House Office of National Drug Control Policy 750 17th Street, N.W. Washington,
More informationPatient and Family Agreement on Opioids
Patient and Family Agreement on Opioids We care about our patients and are committed to their recovery and wellness. We offer our patients medications and options for various services to keep them from
More informationFDA s Response to the Opioid Crisis and the FDA Safe Use Initiative
FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative Scott K. Winiecki, MD Professional Affairs and Stakeholder Engagement Staff (PASES) Center For Drug Evaluation and Research (CDER) U.S.
More informationHL3.01 REPORT FOR ACTION. Toronto Indigenous Overdose Strategy SUMMARY
HL3.01 REPORT FOR ACTION Toronto Indigenous Overdose Strategy Date: February 6, 2019 To: Board of Health From: Medical Officer of Health Wards: All SUMMARY The opioid poisoning crisis continues unabated
More informationRe: May 2018 Consultation Paper, Professional Skepticism Meeting Public Expectations
Chartered Professional Accountants of Canada 277 Wellington Street West Toronto ON CANADA M5V 3H2 T. 416 977.3222 F. 416 977.8585 www.cpacanada.ca Comptables professionnels agréés du Canada 277, rue Wellington
More informationDEA: Combating the Supply
Drug Enforcement Administration DEA: Combating the Supply 2nd Annual Opioid Abuse and Heroin Overdose Solutions Summit Cathy Gallagher Diversion Program Manager Detroit Division May 11, 2017 1 Prescription
More informationDraft Regulation R-013: Spousal Exemption to Sexual Abuse Provisions and Draft Standard of Practice S-032: Providing Chiropractic Care to a Spouse
ONTARIO CHIROPRACTIC ASSOCIATION ASSOCIATION CHIROPRATIQUE DE L ONTARIO March 26, 2015 Joel Friedman, Director, Policy and Research College of Chiropractors of Ontario 130 Bloor St. West, Suite 902 Toronto,
More information9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A
Prescription Drug Abuse Crises Outline 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A 1 1970s 1980s 2 The 1990s OXYCODONE Oxycodone/APAP OxyContin
More informationHL18.3 REPORT FOR ACTION. Toronto Overdose Action Plan: Prevention & Response SUMMARY
HL18.3 REPORT FOR ACTION Toronto Overdose Action Plan: Prevention & Response Date: March 10, 2017 To: Board of Health From: Acting Medical Officer of Health Wards: All SUMMARY At its meeting of December
More informationOXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003
OXYCONTIN Diversion & Abuse Office of Diversion Control October 2003 OXYCONTIN OxyContin is a controlled release form of Schedule II oxycodone Manufactured in tablet form and intended for oral ingestion
More informationAlthough PDMPs are separately managed and maintained by each state or jurisdiction, the national network facilitates more uniformity among states.
NASCSA Statement for the Record as presented by Barbara A Carter, President, NASCSA Submitted to: Department of Health and Human Services, Food and Drug Administration, Opioid Policy Steering Committee
More informationSummary of responses: Consultation on determining the amount of a variable monetary penalty. April 2017
Summary of responses: Consultation on determining the amount of a variable monetary penalty April 2017 1. Introduction 1.1 One of SEPA s most important roles, as Scotland s principal environmental regulator,
More informationMedication Guide Fentanyl transdermal system, CII Rx Only Fentanyl transdermal system is: A strong prescription pain medicine that contains an opioid
Medication Guide Fentanyl transdermal system, CII Rx Only Fentanyl transdermal system is: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough
More informationOPIOID EMERGENCY RESPONSE REGULATION
Province of Alberta PUBLIC HEALTH ACT OPIOID EMERGENCY RESPONSE REGULATION Alberta Regulation 99/2017 With amendments up to and including Alberta Regulation 87/2018 Office Consolidation Published by Alberta
More informationThe Society welcomes the opportunity to respond the Department of Health s consultation on generic substitution.
Lindsey Gilpin Chairman of the English Pharmacy Board Telephone: 020 7572 2519 Fax: 0207 572 2501 e-mail: howard.duff@rpsgb.org 25 th March 2010 Dear Sir/Madam, Consultation on the proposals to implement
More informationToday s Presenters. Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care
Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care 203 - Monday, April 16, 2018 Today s Presenters Ben Purser Former F.B.I. Special Agent Donna Thiel ProviderTrust Chief
More informationGuideline for the Rational Use of Controlled Drugs
Guideline for the Rational Use of Controlled Drugs Ministry of Health Male' Republic of Maldives April 2000 Table of Contents Page Introduction.. 2 1. Procurement and Supply of Controlled Drugs 3 1.1 Import
More informationOfficer Al Fear Eastern Iowa Heroin Initiative Cedar Rapids Police Department U.S. Attorney s Office NDIA
Officer Al Fear Eastern Iowa Heroin Initiative Cedar Rapids Police Department U.S. Attorney s Office NDIA Angie Asa-Lovstad, MS, CTF, CPS Co-Director, Alliance of Coalitions for Change (AC4C) Certified
More information1) Louisiana s Opioid Addiction 2) Adopting a Drug Formulary - HB 592 3) What is the ODG Drug Formulary and How is it Used in Workers Comp 4) The
1) Louisiana s Opioid Addiction 2) Adopting a Drug Formulary - HB 592 3) What is the ODG Drug Formulary and How is it Used in Workers Comp 4) The Role of Diagnosis (how it will work with the current treatment
More informationSafe States Alliance 2018 Innovative Initiatives Finalist Summaries for Review
Safe States Alliance 2018 Innovative Initiatives Finalist Summaries for Review 1 Initiative #1: Aiming for Equity in Sexual Violence Prevention - Mapping Risks, Policies, Outcomes and Resources Statement
More informationTHE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and
THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and effective. Before any drug is approved for marketing
More informationMinistry of Health and Long-Term Care Overdose Prevention Sites: User Guide for Applicants
Ministry of Health and Long-Term Care Overdose Prevention Sites: User Guide for Applicants Population and Public Health Division Ministry of Health and Long-Term Care January 2018 INTRODUCTION On November
More informationCoversheet: Medicinal cannabis: 100 day action
Coversheet: Medicinal cannabis: 100 day action Advising agencies Decision sought Proposing Ministers Ministry of Health Introduction of Misuse of Drugs Amendment Bill Hon Dr David Clark, Minister of Health
More informationSafe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009
Safe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009 Background and Situation Analysis: Consumers are rightly confused about what to do with their unwanted
More informationChallenges for U.S. Attorneys Offices (USAO) in Opioid Cases
Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Overview On August 2, 2017, U.S. Attorney General Jeff Sessions announced a pilot program whereby a new federal data analysis program is being
More informationEquine Infectious Anemia Disease Control Program. A Report on the Recommendations of the EIA Program Working Group. Canadian Food Inspection Agency
Equine Infectious Anemia Disease Control Program A Report on the Recommendations of the EIA Program Working Group Canadian Food Inspection Agency Animal Health, Welfare and Biosecurity Division Animal
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More information1. Introduction. 2. Role of PSI as Pharmacy Regulator
1. Introduction 1.1. I would like to begin by thanking the Committee for inviting the Pharmaceutical Society of Ireland here today to assist in the Committee s on-going scrutiny of the Cannabis for Medicinal
More information9/3/2013. Presentation Objective. Prescription Drug Abuse Statistics Prescription Drug Abuse Statistics. Pharmaceutical Drugs and the Environment
Presentation Objective Background - Why do we need a regulation for the disposal of controlled substances. Disposal of Controlled Substances DEA Notice of Proposed Rulemaking AHMP 2013 National Conference
More informationMARYLAND BOARD OF PHARMACY
MARYLAND BOARD OF PHARMACY CONTRACEPTION REGULATIONSAnd Other Legislative Initiatives THE ROAD FROM CONCEPTUALIZATION TO IMPLEMENTATION Deena Speights-Napata Executive Director Maryland Board of Pharmacy
More informationNo one should be at risk of poor health because of their social and economic situations.
HEALTH MATTERS No one should be at risk of poor health because of their social and economic situations. Members of municipal government play an important role in shaping policies that impact all aspects
More informationACCG Mental Health Summit
ACCG Mental Health Summit Sheila Pierce, Opioid Program Coordinator Director, Prescription Drug Management Program Discussion 1. Overview Opioid Problem in GA - Video 2. DPH Opioid Program 3. Priorities
More informationDEA and Doctors: Cooperation for the Public Good
Addiction, Pain, & Public Health website - www.doctordeluca.com/ DEA and Doctors: Cooperation for the Public Good Asa Hutchinson, Administrator: Drug Enforcement Agency (DEA); Presentation to the American
More information2004-L SEPTEMBER
BULLETIN INTELLIGENCE Buprenorphine: Potential for Abuse Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III
More informationSafety and Use of Opioids. A summary of ODPRN research on prescription opioid use in Ontario
Safety and Use of Opioids A summary of ODPRN research on prescription opioid use in Ontario The Ontario Drug Policy Research Network 2016 1 About the ODPRN The Ontario Drug Policy Research Network (ODPRN)
More informationUS H.R.6 of the 115 th Congress of the United States Session
US H.R.6 of the 115 th Congress of the United States 2017-2018 Session This Act may be cited as the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities
More informationA Different Kind of Drug War. CINDY SANDERS Posted: Thursday, April 5, :07 pm. Providers Focus on Prescription Drug Addiction, Abuse
A Different Kind of Drug War CINDY SANDERS Posted: Thursday, April 5, 2012 4:07 pm Dr. Roland Gray recording the latest online prescribing class curriculum for the Prescription Safety Program. Providers
More information11/11/2015. MVAs Suicide Firearms Homicide. Where Can I Find A Copy of the PDMP Law? Why Was the Law Established? Why Was the Law Established?
Where Can I Find A Copy of the PDMP Law? Alabama Uniform Controlled Substances Act Code of Alabama 1975 20-2- (Article 10) -210 through 220 and Rules 420-7-2-.11 through.13 1 Why Was the Law Established?
More information